DOCSLIB.ORG

Elucidating the Interplay Between Lipids and Membrane Proteins Using Multiscale Computer Simulations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Elucidating the Interplay Between Lipids and Membrane Proteins Using Multiscale Computer Simulations University of Calgary PRISM: University of Calgary's Digital Repository Graduate Studies The Vault: Electronic Theses and Dissertations 2020-07-30 Elucidating the Interplay Between Lipids and Membrane Proteins Using Multiscale Computer Simulations Sejdiu, Besian I. Sejdiu, B. I. (2020). Elucidating the Interplay Between Lipids and Membrane Proteins Using Multiscale Computer Simulations (Unpublished doctoral thesis). University of Calgary, Calgary, AB. http://hdl.handle.net/1880/112372 doctoral thesis University of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission. Downloaded from PRISM: https://prism.ucalgary.ca UNIVERSITY OF CALGARY Elucidating the Interplay Between Lipids and Membrane Proteins Using Multiscale Computer Simulations by Besian I. Sejdiu A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY GRADUATE PROGRAM IN BIOLOGICAL SCIENCES CALGARY, ALBERTA JULY, 2020 © Besian I. Sejdiu 2020 Abstract Biological membranes are complex cellular structures formed by a large number of different lipid types, that also contain a variety of bound proteins, carbohydrates, and other molecules. The detailed orchestration of all these elements has been a major focus of scientific research during the last 5 decades. Computer- based methods, such as molecular dynamics (MD) simulations, have proven to be a valuable approach in addressing many of the details of lipid organization and membrane protein activity. I used MD simulations at both atomistic and coarse-grained level of detail to study the number of way lipids and proteins interact and their possible functional ramifications. In part of my work, I studied the interaction of G Protein- Coupled Receptors (GPCRs) with lipids at a family-wide level. Plenty of other computational studies had shown specific lipid-protein interactions for a handful of GPCRs but with quite different outcomes on their number, location, and lipid identity. In my work, I simulated 28 different GPCR structures and showed that they are distinguished by a unique interaction profile with membrane lipids. I provided a comprehensive analysis of simulation results with available crystallographic data. I also studied the lipid-protein interaction profile of AMPA receptors and cyclooxygenases (mainly COX-1), showing that they both form specific interactions with lipids, but do so in a quite different fashion. AMPA receptors interact specifically with diacylglycerol lipids, whereas COX-1 enzymes do so indiscriminately with glycerophospholipids, cholesterol, and fatty acids, but at different levels of interaction strength. Using atomistic simulations, we show the binding pathway of arachidonic acid to COX-1 and identify a series of arginine residues that guide it toward the hydrophobic cavity of the enzyme. As part of my work, I also developed a webserver that automates the analysis and visualization of lipid-protein interactions from MD simulations allowing for the creation of automated pipelines to study lipid-protein interactions in the future. Lastly, I provide a short review of some of the main challenges facing the field along with possible solutions going forward. My work expands our understanding of lipid-protein interactions. ii Preface The work presented in this thesis contains four chapters of original research and two reviews, also original work, on the field of lipid-protein interactions. Below I outline the content of each chapter and its status in terms of availability to the general scientific community. Chapter 1 provides a brief introduction to the biology of the problem and the methods I use. It is meant to serve as a general overview of lipid-protein interactions and as an intuitive guideline to MD simulations. Its primary purpose is to allow for an easier reading of later chapters. Chapter 2 includes a detailed review of GPCR-lipid interactions as derived primarily from MD simulations. It contains my contribution on a large and comprehensive review article that was published in Chemical Reviews in 2019. I also reviewed the same literature on bacterial mechanosensitive channels but that is not included in here. Chapter 3 presents the study of lipid-protein interaction profile of AMPA receptors. The work presented in this chapter highlights part of my contribution to a wider collaborative effort that was published in ACS Central Science in 2018. Chapter 4 details my work on the lipid-protein interaction profile of GPCRs. In it, I provide a comparative study of the interaction of 28 different GPCR structures with their lipid environment. Appendix A presents the supplementary information for this chapter. This work has been published in the Biophysical Journal. Chapter 5 includes a detailed study of the lipid interaction profile of COX-1 enzymes. In it, I show how these enzymes bind different membrane lipids in their hydrophobic cavity. I also detail the binding pathway of arachidonic acid to the same binding site. Appendix B contains the supplementary information for this chapter. This work has been made available online on bioRxiv and will be submitted for peer-review soon. Chapter 6 presents a webserver/software that I developed which aims at automating the analysis and visualization of lipid-protein interactions. The chapter provides an overview of some of the analysis applications that have been implemented and discusses the advantages they provide. The manuscript for this work has been completed and will be submitted soon. Chapter 7 provides a short review of the field of lipid-protein interactions. It focuses mainly on the challenges and obstacles facing the field, as well as providing novel analysis and a discussion on how the field should move forward. This work will be submitted for consideration to The Journal of Chemical Physics soon. iii Chapter 8 contains a brief summary of conclusions reached for all chapters. The following is a list of papers and reviews published during my PhD(1-4): 1. Corradi V., E. Mendez-Villuendas, H. I. Ingolfsson, R. X. Gu, I. Siuda, M. N. Melo, A. Moussatova, L. J. DeGagne, B. I. Sejdiu, G. Singh, T. A. Wassenaar, K. D. Magnero, S. J. Marrink, D. P. Tieleman. Lipid-Protein Interactions Are Unique Fingerprints for Membrane Proteins. Acs Central Sci. 2018;4(6):709-717. 2. Corradi V., B. I. Sejdiu, H. Mesa-Galloso, H. Abdizadeh, S. Y. Noskov, S. J. Marrink, D. P. Tieleman. Emerging Diversity in Lipid–Protein Interactions. Chem Rev. 2019. 3. Sejdiu B. I., D. P. Tieleman. Lipid-Protein Interactions Are a Unique Property and Defining Feature of G Protein-Coupled Receptors. Biophys J. 2020;118(8):1887-1900. 4. Sejdiu B. I., D. P. Tieleman. COX-1 - lipid interactions: arachidonic acid, cholesterol, and phospholipid binding to the membrane binding domain of COX-1. bioRxiv. 2020. My contributions to each of the chapters presented in this thesis will be highlighted at the beginning of each chapter. iv Acknowledgement First and foremost, I would like to thank my supervisor Dr. Peter Tieleman for his mentoring throughout my PhD. There are many things to be appreciative about working in the Tieleman lab, but perhaps what I am grateful for most was the freedom that I was given to develop as a scientist and the (frankly, quite often misplaced) trust put on me for knowing what I am doing. I was always free to pursue any project of my interest even if they were only tangentially research related. I am also thankful to Peter for not only allowing but actively encouraging me to express myself freely in my scientific work, design projects and structure articles the way I saw fit and for giving me detailed feedback on my work where sometimes I thought I had mistakenly written manuscripts using a red font. A special thanks goes to my former colleagues in Peter’s group: Dr. Gurpreet Singh and Dr. Valentina Corradi for their help and mentorship. Valentina has been an inspiration for me throughout my PhD, and her dedication, organized planning and friendliness are things I will try to emulate in my future career. Similarly, I thank Dr. Anastassiia Moussatova for her support, advice and encouragement, and all other members of the Tieleman lab for their help, collaboration, and friendship. Thanks to my supervisory committee members, Dr. Kenneth Ng and Dr. Justin MacCallum for their advice and mentorship and for always being accommodating to my requests for meetings. I also appreciate the help of the supporting staff and program coordinators at the University of Calgary for making all the dreadful administrative paperwork so easy to deal with. The most important and most heartfelt appreciation goes to my parents for all the sacrifices they made and continue to make for me, my family, and my education. Both are much smarter than me yet neither got to pursue their passion for academic advancement to their desired extent. Their support towards my goals and dreams has been immense, unwavering, consistent, and so far, almost entirely one-sided. Last but not least, I thank my brothers for their love and support and my wife for guiding and always being there for me. Liridona, you left everything behind to follow me and I can never thank you enough for that. You created a home for us and provided far more than your fair share of work
Load more

Recommended publications
  • Covalent Agonists for Studying G Protein-Coupled Receptor Activation
    Covalent agonists for studying G protein-coupled receptor activation Dietmar Weicherta, Andrew C. Kruseb, Aashish Manglikb, Christine Hillera, Cheng Zhangb, Harald Hübnera, Brian K. Kobilkab,1, and Peter Gmeinera,1 aDepartment of Chemistry and Pharmacy, Friedrich Alexander University, 91052 Erlangen, Germany; and bDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305 Contributed by Brian K. Kobilka, June 6, 2014 (sent for review April 21, 2014) Structural studies on G protein-coupled receptors (GPCRs) provide Disulfide-based cross-linking approaches (17, 18) offer important insights into the architecture and function of these the advantage that the covalent binding of disulfide-containing important drug targets. However, the crystallization of GPCRs in compounds is chemoselective for cysteine and enforced by the active states is particularly challenging, requiring the formation of affinity of the ligand-pharmacophore rather than by the elec- stable and conformationally homogeneous ligand-receptor com- trophilicity of the cross-linking function (19). We refer to the plexes. Native hormones, neurotransmitters, and synthetic ago- described ligands as covalent rather than irreversible agonists nists that bind with low affinity are ineffective at stabilizing an because cleavage may be promoted by reducing agents and the active state for crystallogenesis. To promote structural studies on disulfide transfer process is a reversible chemical reaction the pharmacologically highly relevant class
    [Show full text]
  • Membrane Protein Production for Structural Analysis
    Chapter 1 Membrane Protein Production for Structural Analysis Isabelle Mus-Veteau, Pascal Demange and Francesca Zito 1.1 Introduction Integral membrane proteins (IMPs) account for roughly 30 % of all open reading frames in fully sequenced genomes (Liu and Rost 2001). These proteins are of main importance to living cells. They are involved in fundamental biological processes like ion, water, or solute transport, sensing changes in the cellular environment, signal transduction, and control of cell–cell contacts required to maintain cellular homeostasis and to ensure coordinated cellular activity in all organisms. IMP dys- functions are responsible for numerous pathologies like cancer, cystic fibrosis, epi- lepsy, hyperinsulinism, heart failure, hypertension, and Alzheimer diseases. How- ever, studies on these and other disorders are hampered by a lack of information about the involved IMPs. Thus, knowing the structure of IMPs and understanding their molecular mechanism not only is of fundamental biological interest but also holds great potential for enhancing human health. This is of paramount importance in the pharmaceutical industry, which produces many drugs that bind to IMPs, and recognizes the potential of many recently identified G-protein-coupled receptors (GPCRs), ion channels, and transporters, as targets for future drugs. GPCR, which account for 50 % of all drug targets, is one of the largest and most diverse IMP families encoded by more than 800 genes in the human genome (Fredriksson et al. 2003; Lundstrom 2006). However, whereas high-resolution structures are avail- able for a myriad of soluble proteins (more than 42,000 in the Protein Data Bank, I. Mus-Veteau () Institute for Molecular and Cellular Pharmacology, UMR-CNRS 7275, University of Nice-Sophia Antipolis, Valbonne, France e-mail: [email protected] P.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Nanodiscs in Membrane Biochemistry and Biophysics
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Chem Rev Manuscript Author . Author manuscript; Manuscript Author available in PMC 2018 March 22. Published in final edited form as: Chem Rev. 2017 March 22; 117(6): 4669–4713. doi:10.1021/acs.chemrev.6b00690. NANODISCS IN MEMBRANE BIOCHEMISTRY AND BIOPHYSICS Ilia G. Denisov and Stephen G. Sligar Department of Biochemistry and Department of Chemistry, University of Illinois, Urbana, IL, 61801 Abstract Membrane proteins play a most important part in metabolism, signaling, cell motility, transport, development, and many other biochemical and biophysical processes which constitute fundamentals of life on molecular level. Detailed understanding of these processes is necessary for the progress of life sciences and biomedical applications. Nanodiscs provide a new and powerful tool for a broad spectrum of biochemical and biophysical studies of membrane proteins and are commonly acknowledged as an optimal membrane mimetic system which provides control over size, composition and specific functional modifications on nanometer scale. In this review we attempted to combine a comprehensive list of various applications of Nanodisc technology with systematic analysis of the most attractive features of this system and advantages provided by Nanodiscs for structural and mechanistic studies of membrane proteins. Table of Content Figure An Introduction to Nanodiscs Membrane proteins are represented by a tremendous variety of sizes, structures and functions, including complex supra-molecular
    [Show full text]
  • Antagonist Functional Selectivity: 5-Ht2a
    JPET Fast Forward. Published on July 7, 2011 as DOI: 10.1124/jpet.111.183780 JPETThis Fast article Forward. has not been Published copyedited and on formatted. July 7, The 2011 final as version DOI:10.1124/jpet.111.183780 may differ from this version. JPET#183780 ANTAGONIST FUNCTIONAL SELECTIVITY: 5-HT2A SEROTONIN RECEPTOR ANTAGONISTS DIFFERENTIALLY REGULATE 5-HT2A RECEPTOR PROTEIN LEVEL IN VIVO Prem N. Yadav, Wesley K. Kroeze, Martilias S. Farrell and Bryan L. Roth Downloaded from Departments of Pharmacology (.PN.Y.,W.K.K., M.S.F., B.L.R.,), Medicinal Chemistry jpet.aspetjournals.org (B.L.R.) and Psychiatry (B.L.R.), and Program in Neurosciences and NIMH Psychoactive Drug Screening Program(B.L.R.), University of North Carolina - Chapel Hill Medical School, Chapel Hill, NC 27759 at ASPET Journals on September 29, 2021 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on July 7, 2011 as DOI: 10.1124/jpet.111.183780 This article has not been copyedited and formatted. The final version may differ from this version. JPET#183780 Running title: Functional Selectivity of 5-HT2A receptor antagonists Corresponding Author: Bryan L. Roth MD, PhD Department of Pharmacology UNC Chapel Hill Medical School 4072 Genetic Medicine Building 120 Mason Farm Road Chapel Hill, NC 27599 Fax: 919-843-5788 Downloaded from Tel: 919-966-7535 (Office) Email: [email protected] ; Number of text pages: 26 jpet.aspetjournals.org Number of tables: 0 Number of figures: 5 Number of references: 39 at ASPET Journals on September 29, 2021 Nnumber of words: Abstract: 157 Introduction: 666, Discussion : 485 Abbreviations: 5-HT2A (serotonin 2A); PCP (phencyclidine)", GPCR (G Protein Coupled Receptor) Recommended section: Neuropharmacology 2 JPET Fast Forward.
    [Show full text]
  • 2-Adrenergic Receptor Is Determined by Conformational Equilibrium in the Transmembrane Region
    ARTICLE Received 21 Mar 2012 | Accepted 2 Aug 2012 | Published 4 Sep 2012 DOI: 10.1038/ncomms2046 Efficacy of theβ 2-adrenergic receptor is determined by conformational equilibrium in the transmembrane region Yutaka Kofuku1,2, Takumi Ueda1, Junya Okude1, Yutaro Shiraishi1, Keita Kondo1, Masahiro Maeda3, Hideki Tsujishita3 & Ichio Shimada1,4 Many drugs that target G-protein-coupled receptors (GPCRs) induce or inhibit their signal transduction with different strengths, which affect their therapeutic properties. However, the mechanism underlying the differences in the signalling levels is still not clear, although several structures of GPCRs complexed with ligands determined by X-ray crystallography are available. Here we utilized NMR to monitor the signals from the methionine residue at position 82 in neutral antagonist- and partial agonist-bound states of β2-adrenergic receptor (β2AR), which are correlated with the conformational changes of the transmembrane regions upon activation. We show that this residue exists in a conformational equilibrium between the inverse agonist- bound states and the full agonist-bound state, and the population of the latter reflects the signal transduction level in each ligand-bound state. These findings provide insights into the multi-level signalling of β2AR and other GPCRs, including the basal activity, and the mechanism of signal transduction mediated by GPCRs. 1 Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. 2 Japan Biological Informatics Consortium (JBIC), Tokyo 135-0064, Japan. 3 Shionogi Co., Ltd., Discovery Research Laboratories, Osaka 561-0825, Japan. 4 Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Aomi 2-41-6, Koto-ku, Tokyo 135-0064, Japan.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Final Program and Book of Abstracts
    JOINT MEETING OF THE AUSTRIAN AND GERMAN PHARMACEUTICAL SOCIETIES September 20 – 23, 2011 University of Innsbruck, Austria "Shaping the future – Trends and perspectives in pharmaceutical sciences" FINAL PROGRAM AND BOOK OF ABSTRACTS ORGANIZATION Presidents Prof. H. Stuppner, Innsbruck (ÖPhG) Prof. M. Schubert-Zsilavecz (DPhG) Organizing Committee Prof. G. Ecker (Austria) Prof. S. Glasl-Tazreiter (Austria) Prof. U. Griesser (Austria) Ing. E. Gstrein (Austria) S. Handke (Germany) Dr. T. Maschke (Germany) Dr. S. Schwaiger (Austria) Dr. M. Stein (Germany) Scientific Committee Prof. S. Alban (Vice President, DPhG) Prof. R. Bauer (Graz, Austria) Prof. A. Bernkop-Schnürch (Innsbruck, Austria) Prof. T. Dingermann (Frankfurt, Germany) Prof. Dr. V. Dirsch (Vienna, Austria) Prof. G. Ecker (Vice President,ÖPhG) Prof. S. Glasl-Tazreiter (General Secretary, ÖPhG) Prof. R. Gust (Innsbruck, Austria) Prof. U. Holzgrabe (Würzburg, Germany) Prof. A. Kungl (Graz, Austria) Prof. R. Lemmens-Gruber (Vienna, Austria) Prof. A. Link (General Secretary, DPhG) Prof. C. Noe (Vienna, Austria) Prof. M. Schubert-Zsilavecz (President, DPhG) Prof. N. Singewald (Innsbruck, Austria) Prof. D. Steinhilber (Frankfurt, Germany) Prof. H. Stuppner (President, ÖPhG) Prof. H. Viernstein (Vienna, Austria) Prof. O. Werz (Jena, Germany) Prof. A. Zimmer (Graz, Austria) Organizing Secretariat University of Innsbruck Institute of Pharmacy/Pharmacognosy Innrain 52c A-6020 Innsbruck Email: [email protected] Homepage: www.uibk.ac.at/news/oephg-dphg2011 CONFERENCE VENUES University
    [Show full text]
  • For the Degree of DOCTOR of PHILOSOPHY Science Faculty
    SYNTHESIS OF BIOLOGICALLY ACTIVE NATURAL PRODUCTS AND PHARMACOLOGICALLY ACTIVE MOLECULES BY COMBINATORIAL CHEMISTRY A THESIS Submitted to the SHIVAJI UNIVERSITY, KOLHAPUR For the Degree of DOCTOR OF PHILOSOPHY in CHEMISTRY Science Faculty By ANIL M. DESHPANDE Under the Guidance of Dr. A. A. NATU Division of Organic Chemistry (Synthesis) National Chemical Laboratory Pune 411 008 SEPTEMBER 2001 DEDICATED To My Parents For Their Warmth, Humor And Ethics CERTIFICATE This is to certify that the thesis entitled “SYNTHESIS OF BIOLOGICALLY ACTIVE NATURAL PRODUCTS AND PHARMACOLOGICALLY ACTIVE MOLECULES BY COMBINATORIAL CHEMISTRY” which is being submitted herewith for the award of the Degree of Philosophy in Chemistry of Shivaji University, Kolhapur is the result of the original research work completed by Mr. Anil M. Deshpande under my supervision and guidance at the National Chemical Laboratory, Pune and to the best of my knowledge and belief the work embodied in this thesis has not formed earlier the basis for the award of any Degree or similar title of this or any other University or examining body. (A. A. Natu) Research Guide September 2001 Scientist, Division of Organic Chemistry (Synthesis) National Chemical Laboratory Pune 411 008. DECLARATION I hereby declare that the thesis entitled “SYNTHESIS OF BIOLOGICALLY ACTIVE NATURAL PRODUCTS AND PHARMACOLOGICALLY ACTIVE MOLECULES BY COMBINATORIAL CHEMISTRY” completed and written by me has not previously formed the basis for the award of any Degree or Diploma or other similar title of this or any other University or examining body. (Anil M. Deshpande) Division of Organic Chemistry (Synthesis) September 2001 National Chemical Laboratory Pune 411 008.
    [Show full text]
  • Glutamate-Gated Chloride Channel Receptors and Mechanisms of Drug Resistance in Pathogenic Species
    Glutamate-gated chloride channel receptors and mechanisms of drug resistance in pathogenic species Mohammed Atif B. Pharmacy, M. Pharmacy (Pharmacology) A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2019 Queensland Brain Institute Dedicated to my beloved parents & my demised brother who I miss everyday ii Thesis Abstract Pentameric ligand-gated ion channels (pLGICs) are important therapeutic targets for a wide range of neurological disorders that include cognitive impairment, stroke, psychiatric conditions and peripheral pain. They are also targets for treating parasite infections and controlling pest species in agriculture, veterinary practice and human health. Here we focus on one family of the pLGICs i.e., the glutamate-gated chloride channel receptors (GluClRs) which are expressed at inhibitory synapses of invertebrates. Ivermectin (IVM) is one of the main drugs used to control pest species and parasites, and it works by activating GluClRs in nematode and arthropod muscle and nerves. IVM resistance is becoming a major problem in many invertebrate pathogens, necessitating the development of novel anti-parasitic drugs. This project started with the simple aim of determining the sensitivity to glutamate and IVM of GluClRs from two different pest species: the parasitic nematode Haemonchus contortus (HcoGluClRs) and the mosquito malaria vector Anopheles gambiae (AgGluClRs). In chapter 3, we found that the β homomeric GluClRs of H.contortus were insensitive to IVM (EC50> 10 µM), whereas α homomeric HcoGluClRs were highly sensitive (EC50 = 20 nM). Heteromeric αβ HcoGluClRs exhibited an intermediate sensitivity to IVM (EC50 = 135 nM). By contrast, the EC50 values for glutamate at α homomeric and αβ heteromeric receptors were not distinguishable; falling between 20-30 µM.
    [Show full text]
  • Challenges of Antibacterial Discovery Lynn L
    CLINICAL MICROBIOLOGY REVIEWS, Jan. 2011, p. 71–109 Vol. 24, No. 1 0893-8512/11/$12.00 doi:10.1128/CMR.00030-10 Copyright © 2011, American Society for Microbiology. All Rights Reserved. Challenges of Antibacterial Discovery Lynn L. Silver* LL Silver Consulting, LLC, 955 S. Springfield Ave., Unit C403, Springfield, New Jersey 07081 INTRODUCTION .........................................................................................................................................................72 The Discovery Void...................................................................................................................................................72 Class Modifications versus Novel Classes.............................................................................................................72 BACKGROUND............................................................................................................................................................72 Early Screening—a Brief and Biased Philosophical History .............................................................................72 The Rate-Limiting Steps of Antibacterial Discovery ...........................................................................................74 The Multitarget Hypothesis ....................................................................................................................................74 ANTIBACTERIAL RESISTANCE ..............................................................................................................................75
    [Show full text]
  • Epigenetics of Aging and Alzheimer's Disease
    Review Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response Ramón Cacabelos 1,2,* and Clara Torrellas 1,2 Received: 30 September 2015; Accepted: 8 December 2015; Published: 21 December 2015 Academic Editor: Sabrina Angelini 1 EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, 15165-Bergondo, Corunna, Spain; [email protected] 2 Chair of Genomic Medicine, Camilo José Cela University, 28692-Madrid, Spain * Correspondence: [email protected]; Tel.: +34-981-780505 Abstract: Epigenetic variability (DNA methylation/demethylation, histone modifications, microRNA regulation) is common in physiological and pathological conditions. Epigenetic alterations are present in different tissues along the aging process and in neurodegenerative disorders, such as Alzheimer’s disease (AD). Epigenetics affect life span and longevity. AD-related genes exhibit epigenetic changes, indicating that epigenetics might exert a pathogenic role in dementia. Epigenetic modifications are reversible and can potentially be targeted by pharmacological intervention. Epigenetic drugs may be useful for the treatment of major problems of health (e.g., cancer, cardiovascular disorders, brain disorders). The efficacy and safety of these and other medications depend upon the efficiency of the pharmacogenetic process in which different clusters of genes (pathogenic, mechanistic, metabolic, transporter, pleiotropic) are involved. Most of these genes are also under the influence of the epigenetic machinery. The information available on the pharmacoepigenomics of most drugs is very limited; however, growing evidence indicates that epigenetic changes are determinant in the pathogenesis of many medical conditions and in drug response and drug resistance. Consequently, pharmacoepigenetic studies should be incorporated in drug development and personalized treatments.
    [Show full text]